Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 220.00 | 1.96% | 11,416.00 | 11,412.00 | 11,414.00 | 11,442.00 | 11,226.00 | 11,226.00 | 1,382,390 | 16:35:12 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 54.07B | 7.04B | 4.5370 | 25.16 | 173.6B |
From Mar 2020 to Mar 2025
By Tapan Panchal
LONDON--AstraZeneca PLC (AZN.LN) said Wednesday that its asthma treatment drug tralokinumab didn't meet its primary endpoint in a clinical trial.
Tralokinumab didn't demonstrate a significant reduction in the annual rate of asthma attacks in the first of two Phase III clinical trials, the pharmaceutical company said. The results of the second trial are expected in the second half of 2017.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
May 10, 2017 02:48 ET (06:48 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
